메뉴 건너뛰기




Volumn 8, Issue 8, 2012, Pages 1015-1029

EGF receptor-targeted therapy in non-small-cell lung cancer: Role of germline polymorphisms in outcome and toxicity

Author keywords

EGFR tyrosine kinase inhibitor; erlotinib; gefitinib; non small cell lung cancer; outcome; polymorphism; toxicity

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; GEMCITABINE; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN KINASE B; TRANSCRIPTION FACTOR SP1;

EID: 84865243290     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.89     Document Type: Review
Times cited : (24)

References (79)
  • 1
    • 80052755036 scopus 로고    scopus 로고
    • Thymidylate synthase inhibitors for non-small cell lung cancer
    • Galvani E, Peters GJ, Giovannetti E. Thymidylate synthase inhibitors for non-small cell lung cancer. Expert Opin Investig. Drug 20(10), 1343-1356 (2011).
    • (2011) Expert Opin Investig. Drug , vol.20 , Issue.10 , pp. 1343-1356
    • Galvani, E.1    Peters, G.J.2    Giovannetti, E.3
  • 2
    • 62449124416 scopus 로고    scopus 로고
    • Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer
    • Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 27(8), 1227-1234 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , Issue.8 , pp. 1227-1234
    • Reck, M.1    Von Pawel, J.2    Zatloukal, P.3
  • 3
    • 49049089802 scopus 로고    scopus 로고
    • Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
    • Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26(21), 3543-3551 (2008).
    • (2008) J. Clin. Oncol. , vol.26 , Issue.21 , pp. 3543-3551
    • Scagliotti, G.V.1    Parikh, P.2    Von Pawel, J.3
  • 4
    • 0035810147 scopus 로고    scopus 로고
    • Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
    • Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344(14), 1031-1037 (2001).
    • (2001) N. Engl. J. Med. , vol.344 , Issue.14 , pp. 1031-1037
    • Druker, B.J.1    Talpaz, M.2    Resta, D.J.3
  • 5
    • 33744493376 scopus 로고    scopus 로고
    • Targeting tyrosine kinases in cancer: The second wave
    • Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 312(5777), 1175-1178 (2006).
    • (2006) Science , vol.312 , Issue.5777 , pp. 1175-1178
    • Baselga, J.1
  • 6
    • 0036685211 scopus 로고    scopus 로고
    • Advanced NSCLC: From cytotoxic systemic chemotherapy to molecularly targeted therapy
    • Hoang T, Schiller JH. Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy. Expert Rev. Anticancer Ther. 2(4), 393-401 (2002).
    • (2002) Expert Rev. Anticancer Ther. , vol.2 , Issue.4 , pp. 393-401
    • Hoang, T.1    Schiller, J.H.2
  • 8
    • 18344390418 scopus 로고    scopus 로고
    • ERBB receptors and cancer: The complexity of targeted inhibitors
    • Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5(5), 341-354 (2005).
    • (2005) Nat. Rev. Cancer , vol.5 , Issue.5 , pp. 341-354
    • Hynes, N.E.1    Lane, H.A.2
  • 9
    • 14744281693 scopus 로고    scopus 로고
    • Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study
    • Suzuki S, Dobashi Y, Sakurai H, Nishikawa K, Hanawa M, Ooi A. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study. Cancer 103(6), 1265-1273 (2005).
    • (2005) Cancer , vol.103 , Issue.6 , pp. 1265-1273
    • Suzuki, S.1    Dobashi, Y.2    Sakurai, H.3    Nishikawa, K.4    Hanawa, M.5    Ooi, A.6
  • 10
    • 0142119289 scopus 로고    scopus 로고
    • Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis
    • Hirsch FR, Varella-Garcia M, Bunn PA et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 21(20), 3798-3807 (2003).
    • (2003) J. Clin. Oncol. , vol.21 , Issue.20 , pp. 3798-3807
    • Hirsch, F.R.1    Varella-Garcia, M.2    Bunn, P.A.3
  • 11
    • 0142055937 scopus 로고    scopus 로고
    • Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial
    • Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290(16), 2149-2158 (2003).
    • (2003) JAMA , vol.290 , Issue.16 , pp. 2149-2158
    • Kris, M.G.1    Natale, R.B.2    Herbst, R.S.3
  • 12
    • 2342471392 scopus 로고    scopus 로고
    • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    • Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004).
    • (2004) N. Engl. J. Med. , vol.350 , Issue.21 , pp. 2129-2139
    • Lynch, T.J.1    Bell, D.W.2    Sordella, R.3
  • 13
    • 22044453790 scopus 로고    scopus 로고
    • Erlotinib in lung cancer-molecular and clinical predictors of outcome
    • Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N. Engl. J. Med. 353(2), 133-144 (2005).
    • (2005) N. Engl. J. Med. , vol.353 , Issue.2 , pp. 133-144
    • Tsao, M.S.1    Sakurada, A.2    Cutz, J.C.3
  • 14
    • 33847323129 scopus 로고    scopus 로고
    • Epidermal growth factor receptor mutations in lung cancer
    • Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7(3), 169-181 (2007).
    • (2007) Nat. Rev. Cancer , vol.7 , Issue.3 , pp. 169-181
    • Sharma, S.V.1    Bell, D.W.2    Settleman, J.3    Haber, D.A.4
  • 16
    • 0035939330 scopus 로고    scopus 로고
    • Studies leading to the identification of ZD1839 (IRESSA): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
    • Barker AJ, Gibson KH, Grundy W et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg. Med. Chem. Lett. 11(14), 1911-1914 (2001).
    • (2001) Bioorg. Med. Chem. Lett. , vol.11 , Issue.14 , pp. 1911-1914
    • Barker, A.J.1    Gibson, K.H.2    Grundy, W.3
  • 17
    • 0037211253 scopus 로고    scopus 로고
    • Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): Simple drugs with a complex mechanism of action?
    • Normanno N, Maiello MR, De Luca A. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action? J. Cell. Physiol. 194(1), 13-19 (2003).
    • (2003) J. Cell. Physiol. , vol.194 , Issue.1 , pp. 13-19
    • Normanno, N.1    Maiello, M.R.2    De Luca, A.3
  • 18
    • 3042665929 scopus 로고    scopus 로고
    • The biology of epidermal growth factor receptor in lung cancer
    • Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin. Cancer Res. 10(12 Pt 2), 4227s-4232s (2004).
    • (2004) Clin. Cancer Res. , vol.10 , Issue.12 PART 2
    • Scagliotti, G.V.1    Selvaggi, G.2    Novello, S.3    Hirsch, F.R.4
  • 19
    • 56249109644 scopus 로고    scopus 로고
    • Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised Phase III trial
    • Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised Phase III trial. Lancet 372(9652), 1809-1818 (2008).
    • (2008) Lancet , vol.372 , Issue.9652 , pp. 1809-1818
    • Kim, E.S.1    Hirsh, V.2    Mok, T.3
  • 20
    • 22044445517 scopus 로고    scopus 로고
    • Erlotinib in previously treated non-small-cell lung cancer
    • Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005).
    • (2005) N. Engl. J. Med. , vol.353 , Issue.2 , pp. 123-132
    • Shepherd, F.A.1    Rodrigues Pereira, J.2    Ciuleanu, T.3
  • 21
    • 69949162760 scopus 로고    scopus 로고
    • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    • Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
    • (2009) N. Engl. J. Med. , vol.361 , Issue.10 , pp. 947-957
    • Mok, T.S.1    Wu, Y.L.2    Thongprasert, S.3
  • 22
    • 33845803204 scopus 로고    scopus 로고
    • Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels
    • Helfrich BA, Raben D, Varella-Garcia M et al. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin. Cancer Res. 12(23), 7117-7125 (2006).
    • (2006) Clin. Cancer Res. , vol.12 , Issue.23 , pp. 7117-7125
    • Helfrich, B.A.1    Raben, D.2    Varella-Garcia, M.3
  • 23
    • 70350772288 scopus 로고    scopus 로고
    • Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects
    • Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects. Curr. Drug Metab. 10(5), 470-481 (2009).
    • (2009) Curr. Drug Metab. , vol.10 , Issue.5 , pp. 470-481
    • Hartmann, J.T.1    Haap, M.2    Kopp, H.G.3    Lipp, H.P.4
  • 24
    • 34247477205 scopus 로고    scopus 로고
    • Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers
    • Nomura M, Shigematsu H, Li L et al. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med. 4(4), e125 (2007).
    • (2007) PLoS Med. , vol.4 , Issue.4
    • Nomura, M.1    Shigematsu, H.2    Li, L.3
  • 25
    • 0028043510 scopus 로고
    • A variant epidermal growth factor receptor exhibits altered type a transforming growth factor binding and transmembrane signaling
    • Moriai T, Kobrin MS, Hope C, Speck L, Korc M. A variant epidermal growth factor receptor exhibits altered type a transforming growth factor binding and transmembrane signaling. Proc. Natl Acad. Sci. USA 91(21), 10217-10221 (1994).
    • (1994) Proc. Natl Acad. Sci. USA , vol.91 , Issue.21 , pp. 10217-10221
    • Moriai, T.1    Kobrin, M.S.2    Hope, C.3    Speck, L.4    Korc, M.5
  • 26
    • 11244319884 scopus 로고    scopus 로고
    • A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter
    • Liu W, Innocenti F, Wu MH et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res. 65(1), 46-53 (2005).
    • (2005) Cancer Res. , vol.65 , Issue.1 , pp. 46-53
    • Liu, W.1    Innocenti, F.2    Wu, M.H.3
  • 27
    • 40949096067 scopus 로고    scopus 로고
    • Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib
    • Liu G, Gurubhagavatula S, Zhou W et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J. 8(2), 129-138 (2008).
    • (2008) Pharmacogenomics J. , vol.8 , Issue.2 , pp. 129-138
    • Liu, G.1    Gurubhagavatula, S.2    Zhou, W.3
  • 28
    • 33846994719 scopus 로고    scopus 로고
    • The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer
    • Ichihara S, Toyooka S, Fujiwara Y et al. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int. J. Cancer 120(6), 1239-1247 (2007).
    • (2007) Int. J. Cancer , vol.120 , Issue.6 , pp. 1239-1247
    • Ichihara, S.1    Toyooka, S.2    Fujiwara, Y.3
  • 29
    • 39449096577 scopus 로고    scopus 로고
    • Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib
    • Gregorc V, Hidalgo M, Spreafico A et al. Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. Clin. Pharmacol. Ther. 83(3), 477-484 (2008).
    • (2008) Clin. Pharmacol. Ther. , vol.83 , Issue.3 , pp. 477-484
    • Gregorc, V.1    Hidalgo, M.2    Spreafico, A.3
  • 30
    • 0033914059 scopus 로고    scopus 로고
    • Modulation of EGFR gene transcription by secondary structures, a polymorphic repetitive sequence and mutations-a link between genetics and epigenetics
    • Gebhardt F, Bürger H, Brandt B. Modulation of EGFR gene transcription by secondary structures, a polymorphic repetitive sequence and mutations-a link between genetics and epigenetics. Histol. Histopathol. 15(3), 929-936 (2000).
    • (2000) Histol. Histopathol. , vol.15 , Issue.3 , pp. 929-936
    • Gebhardt, F.1    Bürger, H.2    Brandt, B.3
  • 31
    • 10844264628 scopus 로고    scopus 로고
    • An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors
    • Amador ML, Oppenheimer D, Perea S et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res. 64(24), 9139-9143 (2004).
    • (2004) Cancer Res. , vol.64 , Issue.24 , pp. 9139-9143
    • Amador, M.L.1    Oppenheimer, D.2    Perea, S.3
  • 32
    • 0040886242 scopus 로고    scopus 로고
    • Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1
    • Gebhardt F, Zänker KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J. Biol. Chem. 274(19), 13176-13180 (1999).
    • (1999) J. Biol. Chem. , vol.274 , Issue.19 , pp. 13176-13180
    • Gebhardt, F.1    Zänker, K.S.2    Brandt, B.3
  • 33
    • 0034652578 scopus 로고    scopus 로고
    • Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression
    • Buerger H, Gebhardt F, Schmidt H et al. Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res. 60(4), 854-857 (2000).
    • (2000) Cancer Res. , vol.60 , Issue.4 , pp. 854-857
    • Buerger, H.1    Gebhardt, F.2    Schmidt, H.3
  • 34
    • 34247281406 scopus 로고    scopus 로고
    • Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer
    • Han SW, Jeon YK, Lee KH et al. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. Pharmacogenet. Genom. 17(5), 313-319 (2007).
    • (2007) Pharmacogenet. Genom. , vol.17 , Issue.5 , pp. 313-319
    • Han, S.W.1    Jeon, Y.K.2    Lee, K.H.3
  • 35
    • 68949208058 scopus 로고    scopus 로고
    • Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with gefitinib
    • Ma F, Sun T, Shi Y et al. Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with gefitinib. Lung Cancer 66(1), 114-119 (2009).
    • (2009) Lung Cancer , vol.66 , Issue.1 , pp. 114-119
    • Ma, F.1    Sun, T.2    Shi, Y.3
  • 36
    • 33846979362 scopus 로고    scopus 로고
    • EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer
    • Dubey S, Stephenson P, Levy DE et al. EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. J. Thorac. Oncol. 1(5), 406-412 (2006).
    • (2006) J. Thorac. Oncol. , vol.1 , Issue.5 , pp. 406-412
    • Dubey, S.1    Stephenson, P.2    Levy, D.E.3
  • 37
    • 34547841540 scopus 로고    scopus 로고
    • The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with gefitinib
    • Nie Q, Wang Z, Zhang GC et al. The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with gefitinib. Eur. J. Pharmacol. 570(1-3), 175-181 (2007).
    • (2007) Eur. J. Pharmacol. , vol.570 , Issue.1-3 , pp. 175-181
    • Nie, Q.1    Wang, Z.2    Zhang, G.C.3
  • 38
    • 58949098405 scopus 로고    scopus 로고
    • Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer
    • Tiseo M, Capelletti M, De Palma G et al. Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer. J. Thorac. Oncol. 3(10), 1104-1111 (2008).
    • (2008) J. Thorac. Oncol. , vol.3 , Issue.10 , pp. 1104-1111
    • Tiseo, M.1    Capelletti, M.2    De Palma, G.3
  • 39
    • 75749153247 scopus 로고    scopus 로고
    • Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers
    • Tiseo M, Rossi G, Capelletti M et al. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers. Lung Cancer 67(3), 355-360 (2010).
    • (2010) Lung Cancer , vol.67 , Issue.3 , pp. 355-360
    • Tiseo, M.1    Rossi, G.2    Capelletti, M.3
  • 40
    • 77949686314 scopus 로고    scopus 로고
    • Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib
    • Giovannetti E, Zucali PA, Peters GJ et al. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol. Cancer Ther. 9(3), 581-593 (2010).
    • (2010) Mol. Cancer Ther. , vol.9 , Issue.3 , pp. 581-593
    • Giovannetti, E.1    Zucali, P.A.2    Peters, G.J.3
  • 41
    • 84862779610 scopus 로고    scopus 로고
    • Pharmacogenetic analysis of BR.21, a placebo-controlled randomized Phase III clinical trial of erlotinib in advanced non-small cell lung cancer
    • Liu G, Cheng D, Ding K et al. Pharmacogenetic analysis of BR.21, a placebo-controlled randomized Phase III clinical trial of erlotinib in advanced non-small cell lung cancer. J. Thorac. Oncol. 7(2), 316-322 (2012).
    • (2012) J. Thorac. Oncol. , vol.7 , Issue.2 , pp. 316-322
    • Liu, G.1    Cheng, D.2    Ding, K.3
  • 42
    • 34250828460 scopus 로고    scopus 로고
    • Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response
    • Tzeng CWD, Frolov A, Frolova N et al. Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response. Ann. Surg. Oncol. 14(7), 2150-2158 (2007).
    • (2007) Ann. Surg. Oncol. , vol.14 , Issue.7 , pp. 2150-2158
    • Cwd, T.1    Frolov, A.2    Frolova, N.3
  • 43
    • 77956189333 scopus 로고    scopus 로고
    • Epidermal growth factor receptor (EGFR) intron 1 polymorphism and clinical outcome in pancreatic adenocarcinoma
    • Frolov A, Liles JS, Kossenkov AV et al. Epidermal growth factor receptor (EGFR) intron 1 polymorphism and clinical outcome in pancreatic adenocarcinoma. Am. J. Surg. 200(3), 398-405 (2010).
    • (2010) Am. J. Surg. , vol.200 , Issue.3 , pp. 398-405
    • Frolov, A.1    Liles, J.S.2    Kossenkov, A.V.3
  • 44
    • 4444332925 scopus 로고    scopus 로고
    • Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer
    • Cappuzzo F, Magrini E, Ceresoli GL et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J. Natl Cancer Inst. 96(15), 1133-1141 (2004).
    • (2004) J. Natl Cancer Inst. , vol.96 , Issue.15 , pp. 1133-1141
    • Cappuzzo, F.1    Magrini, E.2    Ceresoli, G.L.3
  • 45
    • 34250161814 scopus 로고    scopus 로고
    • Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: The ONCOBELL trial
    • Cappuzzo F, Ligorio C, Jänne PA et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J. Clin. Oncol. 25(16), 2248-2255 (2007).
    • (2007) J. Clin. Oncol. , vol.25 , Issue.16 , pp. 2248-2255
    • Cappuzzo, F.1    Ligorio, C.2    Jänne, P.A.3
  • 46
    • 43249115083 scopus 로고    scopus 로고
    • Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias
    • Kim MS, Jeong EG, Yoo NJ, Lee SH. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br. J. Cancer 98(9), 1533-1535 (2008).
    • (2008) Br. J. Cancer , vol.98 , Issue.9 , pp. 1533-1535
    • Kim, M.S.1    Jeong, E.G.2    Yoo, N.J.3    Lee, S.H.4
  • 47
    • 28044453746 scopus 로고    scopus 로고
    • Detection of functional single-nucleotide polymorphisms that affect apoptosis
    • Harris SL, Gil G, Robins H et al. Detection of functional single-nucleotide polymorphisms that affect apoptosis. Proc. Natl Acad. Sci. USA 102(45), 16297-16302 (2005).
    • (2005) Proc. Natl Acad. Sci. USA , vol.102 , Issue.45 , pp. 16297-16302
    • Harris, S.L.1    Gil, G.2    Robins, H.3
  • 48
    • 0842310838 scopus 로고    scopus 로고
    • Convergent evidence for impaired AKT1-GSK3b signaling in schizophrenia
    • Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3b signaling in schizophrenia. Nat. Genet. 36(2), 131-137 (2004).
    • (2004) Nat. Genet. , vol.36 , Issue.2 , pp. 131-137
    • Emamian, E.S.1    Hall, D.2    Birnbaum, M.J.3    Karayiorgou, M.4    Gogos, J.A.5
  • 49
    • 60849109531 scopus 로고    scopus 로고
    • Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy
    • Hildebrandt MAT, Yang H, Hung MC et al. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J. Clin. Oncol. 27(6), 857-871 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , Issue.6 , pp. 857-871
    • Mat, H.1    Yang, H.2    Hung, M.C.3
  • 50
    • 84855347923 scopus 로고    scopus 로고
    • AKT1 polymorphisms and survival of early stage non-small cell lung cancer
    • Kim MJ, Kang HG, Lee SY et al. AKT1 polymorphisms and survival of early stage non-small cell lung cancer. J. Surg. Oncol. 105(2), 167-174 (2012).
    • (2012) J. Surg. Oncol. , vol.105 , Issue.2 , pp. 167-174
    • Kim, M.J.1    Kang, H.G.2    Lee, S.Y.3
  • 51
    • 70449704111 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of tyrosine kinase inhibitors
    • van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat. Rev. 35(8), 692-706 (2012).
    • (2012) Cancer Treat. Rev. , vol.35 , Issue.8 , pp. 692-706
    • Van Erp, N.P.1    Gelderblom, H.2    Guchelaar, H.J.3
  • 52
    • 40349098162 scopus 로고    scopus 로고
    • Drug transporters: Recent advances concerning BCRP and tyrosine kinase inhibitors
    • Lemos C, Jansen G, Peters GJ. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. Br. J. Cancer 98(5), 857-862 (2008).
    • (2008) Br. J. Cancer , vol.98 , Issue.5 , pp. 857-862
    • Lemos, C.1    Jansen, G.2    Peters, G.J.3
  • 53
    • 34548240764 scopus 로고    scopus 로고
    • Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients
    • Li J, Cusatis G, Brahmer J et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol. Ther. 6(3), 432-438 (2007).
    • (2007) Cancer Biol. Ther. , vol.6 , Issue.3 , pp. 432-438
    • Li, J.1    Cusatis, G.2    Brahmer, J.3
  • 54
    • 79951937698 scopus 로고    scopus 로고
    • Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients
    • Lemos C, Giovannetti E, Zucali PA et al. Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics 12(2), 159-170 (2011).
    • (2011) Pharmacogenomics , vol.12 , Issue.2 , pp. 159-170
    • Lemos, C.1    Giovannetti, E.2    Zucali, P.A.3
  • 55
    • 33748435058 scopus 로고    scopus 로고
    • DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
    • Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355(10), 983-991 (2006).
    • (2006) N. Engl. J. Med. , vol.355 , Issue.10 , pp. 983-991
    • Olaussen, K.A.1    Dunant, A.2    Fouret, P.3
  • 56
    • 4444256594 scopus 로고    scopus 로고
    • Single nucleotide polymorphisms and outcome in docetaxel-cisplatin- treated advanced non-small-cell lung cancer
    • Isla D, Sarries C, Rosell R et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol. 15(8), 1194-1203 (2004).
    • (2004) Ann. Oncol. , vol.15 , Issue.8 , pp. 1194-1203
    • Isla, D.1    Sarries, C.2    Rosell, R.3
  • 57
    • 4143051317 scopus 로고    scopus 로고
    • Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
    • Zhou W, Gurubhagavatula S, Liu G et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res. 10(15), 4939-4943 (2004).
    • (2004) Clin. Cancer Res. , vol.10 , Issue.15 , pp. 4939-4943
    • Zhou, W.1    Gurubhagavatula, S.2    Liu, G.3
  • 58
    • 33847127528 scopus 로고    scopus 로고
    • DNA repair and survival in lung cancer-the two faces of Janus
    • Gazdar AF. DNA repair and survival in lung cancer-the two faces of Janus. N. Engl. J. Med. 356(8), 771-773 (2007).
    • (2007) N. Engl. J. Med. , vol.356 , Issue.8 , pp. 771-773
    • Gazdar, A.F.1
  • 59
    • 3042665933 scopus 로고    scopus 로고
    • Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery
    • Rosell R, Felip E, Taron M et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin. Cancer Res. 10(12 Pt 2), 4215s-4219s (2004).
    • (2004) Clin. Cancer Res. , vol.10 , Issue.12 PART 2
    • Rosell, R.1    Felip, E.2    Taron, M.3
  • 60
    • 0031844311 scopus 로고    scopus 로고
    • XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage
    • Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de Murcia J, de Murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol. Cell. Biol. 18(6), 3563-3571 (1998).
    • (1998) Mol. Cell. Biol. , vol.18 , Issue.6 , pp. 3563-3571
    • Masson, M.1    Niedergang, C.2    Schreiber, V.3    Muller, S.4    Menissier-De Murcia, J.5    De Murcia, G.6
  • 61
    • 79959918475 scopus 로고    scopus 로고
    • DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma
    • Han JY, Yoon KA, Park JH et al. DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma. Cancer 117(14), 3201-3208 (2011).
    • (2011) Cancer , vol.117 , Issue.14 , pp. 3201-3208
    • Han, J.Y.1    Yoon, K.A.2    Park, J.H.3
  • 62
    • 24644513947 scopus 로고    scopus 로고
    • Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining?
    • Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J. Clin. Oncol. 23(22), 5235-5246 (2005).
    • (2005) J. Clin. Oncol. , vol.23 , Issue.22 , pp. 5235-5246
    • Peréz-Soler, R.1    Saltz, L.2
  • 63
    • 67349206986 scopus 로고    scopus 로고
    • EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment
    • Huang CL, Yang CH, Yeh KH et al. EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer 64(3), 346-351 (2009).
    • (2009) Lung Cancer , vol.64 , Issue.3 , pp. 346-351
    • Huang, C.L.1    Yang, C.H.2    Yeh, K.H.3
  • 64
    • 41949140593 scopus 로고    scopus 로고
    • Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity
    • Rudin CM, Liu W, Desai A et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J. Clin. Oncol. 26(7), 1119-1127 (2008).
    • (2008) J. Clin. Oncol. , vol.26 , Issue.7 , pp. 1119-1127
    • Rudin, C.M.1    Liu, W.2    Desai, A.3
  • 65
    • 34250749285 scopus 로고    scopus 로고
    • Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma
    • Wang WS, Chen PM, Chiou TJ et al. Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma. Clin. Cancer Res. 13(12), 3597-3604 (2007).
    • (2007) Clin. Cancer Res. , vol.13 , Issue.12 , pp. 3597-3604
    • Wang, W.S.1    Chen, P.M.2    Chiou, T.J.3
  • 66
    • 0345701291 scopus 로고    scopus 로고
    • Bacterial enterotoxins are associated with resistance to colon cancer
    • Pitari GM, Zingman LV, Hodgson DM et al. Bacterial enterotoxins are associated with resistance to colon cancer. Proc. Natl Acad. Sci. USA 100(5), 2695-2699 (2003).
    • (2003) Proc. Natl Acad. Sci. USA , vol.100 , Issue.5 , pp. 2695-2699
    • Pitari, G.M.1    Zingman, L.V.2    Hodgson, D.M.3
  • 67
    • 33845657889 scopus 로고    scopus 로고
    • Pharmacogenetics of ABCG2 and adverse reactions to gefitinib
    • Cusatis G, Gregorc V, Li J et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J. Natl Cancer Inst. 98(23), 1739-1742 (2006).
    • (2006) J. Natl Cancer Inst. , vol.98 , Issue.23 , pp. 1739-1742
    • Cusatis, G.1    Gregorc, V.2    Li, J.3
  • 68
    • 79960804673 scopus 로고    scopus 로고
    • Interstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: Genome-wide analysis of genetic data
    • Nyberg F, Barratt BJ, Mushiroda T et al. Interstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: genome-wide analysis of genetic data. Pharmacogenomics 12(7), 965-975 (2011).
    • (2011) Pharmacogenomics , vol.12 , Issue.7 , pp. 965-975
    • Nyberg, F.1    Barratt, B.J.2    Mushiroda, T.3
  • 69
    • 36749088960 scopus 로고    scopus 로고
    • Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines
    • Liu W, Wu X, Zhang W et al. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin. Cancer Res. 13(22 Pt 1), 6788-6795 (2007).
    • (2007) Clin. Cancer Res. , vol.13 , Issue.22 PART 1 , pp. 6788-6795
    • Liu, W.1    Wu, X.2    Zhang, W.3
  • 70
    • 80755181069 scopus 로고    scopus 로고
    • Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer
    • Brugger W, Triller N, Blasinska-Morawiec M et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 29(31), 4113-4120 (2011).
    • (2011) J. Clin. Oncol. , vol.29 , Issue.31 , pp. 4113-4120
    • Brugger, W.1    Triller, N.2    Blasinska-Morawiec, M.3
  • 71
    • 33645116164 scopus 로고    scopus 로고
    • Cytochrome P450 pharmacogenetics and cancer
    • Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 25(11), 1679-1691 (2006).
    • (2006) Oncogene , vol.25 , Issue.11 , pp. 1679-1691
    • Rodriguez-Antona, C.1    Ingelman-Sundberg, M.2
  • 72
    • 34250694236 scopus 로고    scopus 로고
    • Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes
    • Li J, Zhao M, He P, Hidalgo M, Baker SD. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin. Cancer Res. 13(12), 3731-3737 (2007).
    • (2007) Clin. Cancer Res. , vol.13 , Issue.12 , pp. 3731-3737
    • Li, J.1    Zhao, M.2    He, P.3    Hidalgo, M.4    Baker, S.D.5
  • 73
    • 84859248858 scopus 로고    scopus 로고
    • Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer
    • Hamada A, Sasaki J, Saeki S et al. Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer. Pharmacogenomics 13(5), 615-624 (2012).
    • (2012) Pharmacogenomics , vol.13 , Issue.5 , pp. 615-624
    • Hamada, A.1    Sasaki, J.2    Saeki, S.3
  • 74
    • 72849144434 scopus 로고    scopus 로고
    • Sequencing technologies-the next generation
    • Metzker ML. Sequencing technologies-the next generation. Nat. Rev. Genet. 11(1), 31-46 (2010).
    • (2010) Nat. Rev. Genet. , vol.11 , Issue.1 , pp. 31-46
    • Metzker, M.L.1
  • 75
    • 79953766940 scopus 로고    scopus 로고
    • Tumour evolution inferred by single-cell sequencing
    • Navin N, Kendall J, Troge J et al. Tumour evolution inferred by single-cell sequencing. Nature 472(7341), 90-94 (2011).
    • (2011) Nature , vol.472 , Issue.7341 , pp. 90-94
    • Navin, N.1    Kendall, J.2    Troge, J.3
  • 76
    • 79957468312 scopus 로고    scopus 로고
    • Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy
    • Wu X, Ye Y, Rosell R et al. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J. Natl Cancer Inst. 103(10), 817-825 (2011).
    • (2011) J. Natl Cancer Inst. , vol.103 , Issue.10 , pp. 817-825
    • Wu, X.1    Ye, Y.2    Rosell, R.3
  • 77
    • 84856225885 scopus 로고    scopus 로고
    • Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice
    • Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit. Rev. Oncol. Hematol. 81(2), 103-122 (2012).
    • (2012) Crit. Rev. Oncol. Hematol. , vol.81 , Issue.2 , pp. 103-122
    • Giovannetti, E.1    Erozenci, A.2    Smit, J.3    Danesi, R.4    Peters, G.J.5
  • 78
    • 77953930730 scopus 로고    scopus 로고
    • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    • Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362(25), 2380-2388 (2010).
    • (2010) N. Engl. J. Med. , vol.362 , Issue.25 , pp. 2380-2388
    • Maemondo, M.1    Inoue, A.2    Kobayashi, K.3
  • 79
    • 75249087060 scopus 로고    scopus 로고
    • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised Phase 3 trial
    • Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase 3 trial. Lancet Oncol. 11(2), 121-128 (2010).
    • (2010) Lancet Oncol. , vol.11 , Issue.2 , pp. 121-128
    • Mitsudomi, T.1    Morita, S.2    Yatabe, Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.